



Press Release 2018-08-06

## **Scandion Oncology A/S signs agreement with Sedermera Fondkommission AB regarding an Initial Public Offering at Spotlight Stock Market.**

Scandion Oncology A/S ("Scandion Oncology") hereby announces that an agreement has been signed with Sedermera Fondkommission ("Sedermera") in order to finalize plans for an Initial Public Offering ("IPO") at Spotlight Stock Market ("Spotlight"), Stockholm in the fall of 2018.

"We aim at raising funds to finalize SCO-101 production and to perform the first clinical phase II-study with SCO-101 in women with metastatic breast cancer and taxane resistant disease," says CEO Nils Brünner. "Due to already successful clinical phase I-studies, it will be possible to reach clinical Proof of Concept within approximately 2.5 years from now," Nils Brünner continues.

SCO-101 is a safe and well-tolerated capsule to be taken orally once a day in combination with standard anti-cancer therapy. The addition of SCO-101 to the standard treatment has in preclinical studies shown eradication of drug resistant cancer cells. Of note, drug resistance is considered the most frequent reason for death from cancer. In Denmark, 45 patients die from cancer every day and this number is 64 in Sweden and 3675 in EU. The mission of Scandion Oncology is to reduce the number of deaths from cancer. "I have worked with Sedermera since 2012 when I was CEO for WntResearch AB. Sedermera has proven to have the knowledge and capabilities to successfully introduce small companies to the Spotlight Stock Market. Moreover, Sedermera will closely follow the company and support it with the needed expertise after the IPO. I am therefore fully confident with having Sedermera as our preferred partner in this exciting venture" says CEO Nils Brünner.

**For more information on Scandion Oncology, please contact:**

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: [nb@scandiononcology.com](mailto:nb@scandiononcology.com)

---

**Scandion Oncology** is based on a spin-out from Saniona A/S and University of Copenhagen. The focus is to develop drugs that target and thereby inhibit important drug resistance mechanisms. The most advanced of Scandion Oncology's drugs is SCO-101. This drug has already successfully passed 4 clinical phase I studies and proved to be safe and with only very limited toxicities when given as a daily capsule. SCO-101 has in preclinical studies shown to block important anti-cancer treatment resistance mechanisms rendering drug resistant cancer cells sensitive to treatment. SCO-101 is not cancer type specific but rather specific to common resistance mechanisms. This feature makes the market potential of SCO-101 very large exceeding Euro 4 billion a year in key indications (breast cancer and colorectal cancer). Scandion Oncology's second drug candidate, SCO-201 is presently in preclinical testing and is expected to be used against cancer forms such as lung cancer and pancreatic cancer.